October 17, 2019
BIOINVEST NEWS:
BIOINVEST BREAKING NEWS — We’ve Seen This Before – ZIOP Under Attack By Short Report – REITERATE BUY
Ziopharm stock has been under pressure the past two days as an error-filled Seeking Alpha (a classic site for anonymous bears) short report was released on the internet. The share drop was exacerbated as it came out during the vulnerable tax-loss selling season and right before options expiration. Without going into all the details, the report contained all of the traditional one-sided only nefariously spun comments that include scientific analysis meant to confuse and create fear in a stock mostly owned by retail investors. The report’s attack went after rather ancient history from the old days even before Lawrence Cooper joined as CEO from MD Anderson in 2015. It also valued all three of programs at zero while also claiming that all companies formed from reverse mergers should be questioned as investments (go tell that to MTSL Recommendation MDGL). The report even attacked Dr. Drew Deniger who was recently hired to run ZIOP’s TCR program claiming he was too “young and unproven” despite haven come out of the National Cancer Institute after working with cancer guru Steve Rosenberg. Its so erroneous that the report even went so far as to try and tie to false data that Avexis submitted to the FDA earlier this year. In sum, we have seen this before with many biotech stocks and even MTSL names — ACAD is a class example where shorts called it a zero – and that stock has quadrupled since their bear raid. In our view, this latest bogus will only be remembered as a great buying opportunity. We will discuss more of scientific strengths in the next Issue.
Upcoming near-term catalysts in the remainder of 2019 will be the first patient enrolled in TCR solid tumor trial at the NCI. This should be followed by the Company’s IL-12 data in GBM patients at the 2019 Society for Neuro-Oncology Annual Meeting organized by Society for Neuro-Oncology (SNO) and will be held from November 20 – 24, in Phoenix. Lastly, there is a chance other data to be announced before year end and even some further data at ASH in December. The last time we had a major short attack report was with ACAD and we strongly supported ACAD against that spurious report and which has turned out very well for MTSL subscribers. In our view, will also refute the shorts with fundamental progress just like ACAD and today’s price will be remembered as a steal.